Abstract
Patients with hormone receptor-positive (HR+)/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is unexplored. In this randomized pilot trial, patients with HR+/HER2- breast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab. The primary endpoint was PD-L1 expression change between biopsies. Tumor whole exome/RNA sequencing were performed. Of 29 patients, 72% were node-positive. Residual cancer burden (RCB) 0-1 rate was 28% (inclusive of patients receiving additional neoadjuvant adriamycin/cyclophosphamide). No significant change in PD-L1 expression occurred following nab-paclitaxel or pembrolizumab run-in, thus the primary endpoint was not met. Other secondary outcome measures included overall response rate of 80% to the neoadjuvant regimen, and 3-year event-free survival of 86% (95% CI 69-100%); there were no unexpected safety signals. In exploratory biomarker analyses, higher baseline PD-L1 expression and inflammatory gene signatures were associated with favorable response (RCB 0-1); higher expression of estrogen response genes, with unfavorable response (RCB 2-3).
Introduction
Hormone receptor-positive (HR+), HER2-negative breast cancer is the most common subtype of the disease, yet it remains "immunologically cold" compared to triple-negative breast cancer. These tumors typically exhibit lower PD-L1 expression, fewer tumor-infiltrating lymphocytes (TILs), and a lower mutational burden, making them less responsive to immune checkpoint inhibitors (ICIs). This randomized pilot trial, published in Nature Communications, investigated whether a short "run-in" phase of either chemotherapy or immunotherapy could prime the tumor microenvironment to enhance the efficacy of subsequent combination treatment.
Methods
The study (NCT02999477) was a randomized, open-label pilot trial involving 29 evaluable patients with stage II/III HR+/HER2- breast cancer. Patients were randomized 1:1 to receive a two-week run-in of either nab-paclitaxel (Arm A) or pembrolizumab (Arm B). Following the run-in and a second biopsy, all patients received combined nab-paclitaxel and pembrolizumab. Serial biopsies (baseline, week 3, and week 7) were analyzed using whole-exome sequencing (WES), RNA-seq, and immunohistochemistry for PD-L1 and TILs.
Key Results
The primary endpoint of the trial was the change in tumor cell PD-L1 H-score between baseline and post-run-in biopsies. The study failed to meet this endpoint, as neither chemotherapy nor ICI monotherapy significantly boosted PD-L1 expression or TIL levels during the two-week window (p = 1.00).
Despite the lack of microenvironmental "priming," the trial provided significant clinical and molecular insights:
- Clinical Efficacy: The overall response rate (ORR) was 80%, and the 3-year event-free survival was 86%. The pathologic complete response (pCR) rate was 17% (5/29 patients).
- PD-L1 as a Predictor: pCR rates were markedly higher in patients with baseline PD-L1 Combined Positive Score (CPS) ≥ 10 (43%) compared to those with lower expression.
- Estrogen and Immune Suppression: High expression of estrogen response genes was strongly associated with unfavorable response (Residual Cancer Burden 2-3). Mechanistically, high estrogen signaling correlated with decreased antigen processing and presentation, effectively shielding the tumor from the immune system.
- Inflammatory Signatures and Gut Microbiome: Favorable responses (RCB 0-1) were associated with baseline enrichment in interferon-alpha/gamma and TNF-alpha signaling. Furthermore, exploratory analysis identified gut microbial pathways—specifically arginine and nucleotide synthesis—as strong predictors of response.
Discussion
The failure of the run-in phase to significantly alter PD-L1 expression suggests that the "order of operations" for these agents may be less impactful than hypothesized, or that a longer window is required for observable shifts. However, the identification of estrogen signaling as a major driver of immunotherapy resistance provides a clear roadmap for future research. Combining ICIs with endocrine therapy or targeting the metabolic pathways identified in the gut microbiome may offer new avenues for treating HR+ breast cancer. While limited by a small sample size, this trial offers a high-resolution multi-omic map of the factors dictating immunotherapy response in this challenging subtype.
Summary updated